As part of our leading Drug Discovery series of conferences, join us in October 2024, as the 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of clinical applications, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry.
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.
Rising demand for tissue engineering for personalised, precision medicine is another key driver of this research -- new technologies in the form of organ-on-chip, microphysiological systems and patient-derived tissues are all burgeoning areas of the field.
Don't miss out on the chance to meet with expert leaders driving the industry forward to accelerate drug discovery through advanced in vitro models.
2023 European Edition Speakers Included
- Elad Katz, Lead, Navigate Precision Biology, University of Dundee
- Etienne De Braekeleer, Senior Research Scientist, Astrazeneca
- Ilona Wehl, PostDoc, Boehringer Ingelheim Pharma GmbH & Co. KG
- Jessica Klein, Scientist, Contractor, Genentech
- Lena Brucker, Postdoctoral Scientist, Merck Healthcare KGaA
- Lewis Chaytor, Senior Scientist, Astrazeneca
- Linda Lieberman, Head of Host Pathogen Discovery Research, Merck & Co
- Luca Frenguelli, Director of Biomaterials, Engitix Therapeutics
- Manjunath Hedge, Scientific Investigator & Associate Fellow, GlaxoSmithKline
- Martina Pigoni, Scientist, Roche Innovation Center
- Masato Ohbuchi, Senior Researcher, Astellas Pharma Inc.
- Patrick Devine, Scientific Director, Bristol Myers Squibb
- Pelin Candarlioglu, Cell Biologist/Bioengineer - Complex in Vitro Models, GlaxoSmithKline
- Philip Hewitt, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
- Rhiannon David, Director, Microphysiological Systems, AstraZeneca
- Scott MacDonnell, Director New Target Interrogation Group, Regeneron Pharmaceuticals
- Stefan Przyborski, Professor, Durham University
- Stephen Fowler, Clinical Pharmacologist, Roche Pharmaceuticals
The full agenda is not yet available for this event.
Follow this event to receive an alert when the agenda becomes available.
Venue
Courtyard by Marriott Boston Downtown
275 Tremont St, 02116
Boston, MA, USA
